Filing Details

Accession Number:
0001144204-18-044800
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-08-14 20:00:23
Reporting Period:
2018-08-10
Accepted Time:
2018-08-14 20:00:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1012477 Avadel Pharmaceuticals Plc AVDL Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1600771 L Sandra Hatten Block 10-1, Blanchardstown
Corporate Park, Ballycoolin
Dublin L2 15
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Adss Disposition 2018-08-10 6,290 $4.91 44,010 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Adss 3,400 Indirect By Spouse
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Adss Stock Option (right to buy) $21.67 2025-06-26 100,000 100,000 Direct
Adss Stock Option (right to buy) $14.35 2025-12-10 50,000 50,000 Direct
Adss Stock Option (right to buy) $10.40 2026-12-14 80,000 80,000 Direct
Adss Stock Option (right to buy) $8.95 2027-12-12 60,000 60,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2025-06-26 100,000 100,000 Direct
2025-12-10 50,000 50,000 Direct
2026-12-14 80,000 80,000 Direct
2027-12-12 60,000 60,000 Direct
Footnotes
  1. The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
  2. On August 10, 2018, the reporting person sold 6,290 ADSs in connection with the payment of certain withholding taxes related to the vesting of restricted ADSs that were granted to the reporting person on August 10, 2016 (such grant was reported by the reporting person on a Form 4 filed on August 12, 2016).
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.82 to $5.00, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).
  4. Includes (a) 20,000 restricted ADSs granted under the issuer's "Free Share" award program on 8/10/2016, all of which were issued to the reporting person on the second anniversary of the grant date; (b) 10,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date; and (c) 12,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 8,333 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 4,167 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant).
  5. The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities. The reporting person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
  6. Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 06/26/2015 grant date.
  7. Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.
  8. Options become exercisable as to 20,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
  9. Options become exercisable as to 15,000 ADSs on each of the first four anniversaries after the 12/12/2017 grant date.